6 results
8-K
EX-99.2
RVNC
Revance Therapeutics Inc
14 Oct 20
Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of
8:13am
) 125U (n=125) 250U (n=130) Total (n=301) DEMOGRAPHICS Female (n, %) 29 (63.0) 87 (69.6) 79 (60.8) 195 (64.8) AGE (years) mean (SD) range (min, max … ) Prior BoNT for CD (n, %) 37 (80.4) 108 (86.4) 109 (83.8) 254 (84.4) Demographics and Baseline Characteristics * Other includes Asian (3), American
425
RVNC
Revance Therapeutics Inc
19 May 20
Business combination disclosure
9:48pm
market research showed. We saw that there were consumers across all ages and demographics that were interested in subscriptions. And I think for some
8-K
EX-99.2
cxl8y
4 Dec 18
Entry into a Material Definitive Agreement
8:14am
- Prev
- 1
- Next